Last reviewed · How we verify
Losartan and nebivolol
This combination reduces blood pressure by blocking angiotensin II receptors (losartan) and slowing heart rate through beta-1 adrenergic blockade (nebivolol).
This combination reduces blood pressure by blocking angiotensin II receptors (losartan) and slowing heart rate through beta-1 adrenergic blockade (nebivolol). Used for Hypertension, Heart failure.
At a glance
| Generic name | Losartan and nebivolol |
|---|---|
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Drug class | Angiotensin II receptor antagonist + selective beta-1 adrenergic blocker combination |
| Target | AT1 receptor (losartan); beta-1 adrenergic receptor (nebivolol) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Losartan is an angiotensin II receptor antagonist that blocks vasoconstriction and aldosterone secretion, lowering blood pressure. Nebivolol is a selective beta-1 adrenergic blocker with vasodilatory properties that reduces heart rate and cardiac workload. Together, they provide complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Bradycardia
- Cough
Key clinical trials
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose (PHASE4)
- Treatment of Supine Hypertension in Autonomic Failure (PHASE1)
- Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients (PHASE3)
- Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Losartan and nebivolol CI brief — competitive landscape report
- Losartan and nebivolol updates RSS · CI watch RSS
- Fondazione IRCCS Policlinico San Matteo di Pavia portfolio CI